Back to top
more

Arcus Biosciences (RCUS)

(Delayed Data from NYSE)

$9.23 USD

9.23
425,792

+0.07 (0.76%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $9.23 0.00 (0.00%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak

by Zacks Equity Research

Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.

Zacks Equity Research

Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study

by Zacks Equity Research

Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -4% and 19.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -11.96% and 62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 10.17% and 38.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 10% and 3.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study

by Zacks Equity Research

Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.

Zacks Equity Research

Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases

by Zacks Equity Research

Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.

Zacks Equity Research

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

by Zacks Equity Research

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

Zacks Equity Research

TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

by Zacks Equity Research

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

Zacks Equity Research

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

by Zacks Equity Research

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -2.83% and 4.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

by Zacks Equity Research

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

Zacks Equity Research

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

by Zacks Equity Research

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Zacks Equity Research

Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth

by Zacks Equity Research

Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.

Zacks Equity Research

Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.

Zacks Equity Research

Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall

by Zacks Equity Research

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Zacks Equity Research

Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance

by Zacks Equity Research

Repligen's (RGEN) first-quarter earnings and revenues beat estimates.

Zacks Equity Research

Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus

by Zacks Equity Research

Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.

Zacks Equity Research

Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top

by Zacks Equity Research

Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.

Zacks Equity Research

Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 6.06% and 45.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.

Zacks Equity Research

Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up

by Zacks Equity Research

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.